Codiak BioSciences closes sale of five sets of assets

By Sarah Lizee

Olympia, Wash., June 16 – Codiak BioSciences, Inc. closed the sales of five sets of its assets, according to notices filed Thursday with the U.S. Bankruptcy Court for the District of Delaware.

As previously reported, the company announced the winning and backup bids for the assets following an auction on May 23.

The winning bids include Lonza Houston, Inc.’s $3.4 million bid for lots four and five, Evox Therapeutics Ltd.’s $2.09 million bid for lots two and three, and Astellas Institute for Regenerative Medicine’s $50,000 bid for lot one.

Hercules Capital, Inc. was named backup bidder for all five sets of assets. The bid was a $5 million credit bid.

The court approved the sales on June 6.

Codiak BioSciences is a clinical-stage biopharmaceutical company based in Cambridge, Mass. The company filed bankruptcy on March 27 under Chapter 11 case number 23-10350.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.